Community-based persons with Alzheimer’s disease have a higher risk of fractures, hospitalization, and various comorbidities than persons without the disease.
Published Online: August 07, 2009
Daniel C. Malone, RPh, PhD; Trent P. McLaughlin, PhD; Peter M. Wahl, BA; Christopher Leibman, PharmD; H. Michael Arrighi, PhD; Mark J. Cziraky, PharmD; and Lisa M. Mucha, PhD
Objective: To examine the association of Alzheimer’s disease (AD) with common chronic conditions, acute care events, and risk of hospitalization.
Study Design: Retrospective matched cohort analysis.
Methods: Community-dwelling subjects with a diagnosis of and/or medication for AD were matched to subjects without AD based on age, sex, and geographic region. Administrative claims from commercially insured health plans for medical and pharmacy services provided from January 1, 2000, to March 31, 2006 (inclusive) were analyzed. The Deyo Charlson Index (DCI) was used to assess the number of chronic conditions. The outcomes of interest were risk of fractures and hospitalization.
Results: Among 5396 persons with AD and a matched cohort of 5396 persons without the condition, subjects with AD were more likely to have a diagnosis for any of the DCI components, had a higher rate of fractures (17.7% vs 7.9%, P <.00) and other urgent medical events (eg, pneumonia 14.0% vs 6.3%, P <.00), and were more likely to be hospitalized (odds ratio = 1.7; 95% confidence interval = 1.5, 1.9). There were significant differences in the medication use between the 2 groups, with the use of psychotics/tranquilizers 9-fold higher among persons with AD.
Conclusion: Persons with AD have higher odds of experiencing a fracture, being hospitalized, and requiring other acute care medical services than those without AD. The disease also is associated with a higher prevalence of common chronic conditions.
(Am J Manag Care. 2009;15(8):481-488)
Alzheimer’s disease is a debilitating condition that affects both community and institutionalized elderly persons.
- Persons with newly diagnosed Alzheimer’s disease have a higher prevalence of cardiovascular disease, diabetes, and various other conditions than age- and sex-matched controls.
- The risk of bone fracture is significantly higher among persons with Alzheimer’s disease.
- Persons living in the community with Alzheimer’s disease are hospitalized more frequently than age- and sex-matched controls.
With an aging society, the burden of Alzheimer’s disease (AD) is becoming a greater concern for society and especially healthcare payers. Alzheimer’s disease is typically characterized by progressive memory loss, confusion, and a variety of other cognitive and functional deficits. Although the exact mechanism of AD is not completely understood, recent studies suggest that the presence of beta-amyloid plaques and deposits combined with tangles, twists, or strands of the protein tau may be responsible for neuronal and cognitive loss.1,2 In 2007, the number of persons in the United States with AD was estimated to be approximately 5 million, with more than 24 million worldwide.2,3 The overall prevalence of AD among persons over age 65 years is 5.7%, increasing from approximately 3% for persons age 65 to 70 years to more than 30% for persons age 85 years or older.4,5
The estimated lifetime cost of persons with AD has been estimated to be $174,000.2 In 2005, Medicare spent $91 billion for healthcare for persons with AD, with $21 billion associated with long-term care services.2 The excess cost burden to managed care organizations of persons with AD has been estimated to be more than $4000 per person per year.6
To date, the bulk of the literature on the economic burden of AD has focused on 3 aspects: costs associated with long-term care, informal care costs (ie, the costs associated with loved ones providing around-the-clock care to AD patients living at home), and the incremental impact of AD on the cost of treating other chronic conditions.4,6,7 This body of literature suggests that direct medical costs are primarily focused on the later stages of the disease (long-term care costs) or are associated with more subtle effects such as poor treatment adherence leading to worse outcomes in other illnesses such as diabetes or hypertension. However, AD can be associated with significant events that directly increase medical expenditures. Previous research has shown AD to be a risk factor for falls in the elderly, and hospitalization rates have been shown to increase with increasing AD severity.8-11
The purpose of this analysis was to expand on these reports by providing a more detailed look at resource use in AD patients, focusing on those who still are living in the community and therefore are theoretically at an earlier and less severe stage of disease. Specifically, AD patients and age- and sex-matched peers from a number of managed care plans across the United States were compared with respect to rates of comorbid chronic illness, presence of acute events, pharmacologic treatment, and associated direct medical costs in hopes of providing a broader perspective of the economic impact of AD.
This study used a historical cohort design to examine comorbid conditions and costs among persons with AD and persons without the condition. Administrative claims from commercially insured health plans for medical and pharmacy services provided from January 1, 2000, to March 31, 2006 (inclusive) were analyzed. HealthCore, as a subsidiary of Well-Point Inc, maintains the integrated research database used for the analysis. The data consisted of a deidentified, limited-use data set and were compliant with applicable state and federal laws, including the Health Insurance Portability and Accountability Act, and regulations concerning privacy and security of patient identifiable health information.
During the study period, approximately 20.4 million lives were included in the data set, with 2% coming from the mid- Atlantic, 26% from the southeastern, 8% from the central, and 64% from the western United States; 8% were over age 65 years; and approximately 8% of the total population were individuals participating in Medicare Advantage programs.
Two cohorts were identified: persons with AD and persons without AD. Persons with AD were required to have at least 1 medical claim with a diagnosis indicating AD—based on International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code 331.0x—and/or a pharmacy claim for a cholinesterase inhibitor or memantine. (For a list of the specific agents, see eAppendix A at www.ajmc.com.) Subjects with a diagnosis of alcohol- or drug-induced dementia were excluded, as were subjects with fewer than 24 months of continuous data centered on the first diagnosis or medication claim (index date). The comparison cohort was matched to the AD cohort based on age (± 1 year), sex, and geographic region. Non-AD subjects were assigned an index date that corresponded to that of the matched person with AD. Subjects younger than age 50 years on the index date were excluded from the study. Subjects with AD and no matched non-AD subject were excluded (n = 3027), as were AD patients with prescription claims for acetylcholinesterase inhibitors and/or memantine before their index date (n = 1143).
Comorbid Conditions of Interest
Comorbid conditions were identified based on diagnoses associated with medical encounters. For this study we used the Deyo modification of the Charlson index (DCI).12 Because dementia is one of the conditions contained in the DCI, we excluded diagnosis codes for dementia from the DCI calculation. We also examined the prevalence of other conditions believed to be commonly associated with AD and/or common medical conditions using ICD-9-CM codes (see eAppendix B at www.ajmc.com).
Acute Events of Interest
Using ICD-9-CM codes we evaluated the frequency of infections, injuries, and other acute events occurring during the study period. Fractures were of particular interest because persons with AD are known to be at higher risk of falls. We examined the types of fractures experienced by subjects in both the AD and non-AD groups.
Psychotropic Medication Use
We examined the use of medications that are broadly classified into the therapeutic class of psychotropic medications. For this study psychotropic medications included antiepilepsy therapies, antidepressants, antipsychotics/tranquilizers, anxiolytics/sedatives, hypnotic agents/sleep aids, and narcotic analgesics. These medications were identified via National Drug Code numbers on the pharmacy claims.
We compared the summed DCI score for both the 12 months before and the 12 months after the index date. A nonparametric Savage scores test was used to compare DCI comorbidity scores. The prevalence of each of the specific DCI conditions also was evaluated. The McNemar X2 test for matched pairs was performed to compare the test and control groups for the presence of individual DCI components and other conditions/comorbidities. Where expected cell counts were <5, Fisher exact P values were obtained in the corresponding comparisons. In addition, the presence of conditions considered by the investigators to be clinically relevant to AD was compared between the 2 groups. Because it was hypothesized that fracture diagnoses would be common among the AD cohort, the types of fractures that occurred during the course of the study period were more closely examined to determine whether the incidence differed between skeletal sites. We modeled the risk of any fracture using logistic regression, controlling for comorbid conditions, age, sex, and use of narcotics, antidepressants, anxiolytics/sedatives, antipsychotics, and hypnotics. The prevalence of psychotropic medication use was compared between the groups using the McNemar X2 test. Finally, we also evaluated the risk of hospitalization controlling for age, sex, and comorbid conditions.
A total of 5396 subjects with AD met all inclusion criteria. A cohort of 5396 matched non-AD subjects also were included in the study. Table 1 displays the demographic characteristics of the 2 cohorts. Overall, 38.3% were male and the mean (SD) age was 76.9 (10.2) years; median age for the sample was 78.7 years. For persons in the AD cohort, more than half (n = 3141, 58.2%) were identified as having AD based on medication use, with few subjects (n = 113, 2.1%) having both an AD diagnosis and a prescription claim for an AD medication on the same date. Also, most AD patients (n = 4242, 78.6%) had 2 or more AD claims during the study period.
As shown in Table 2, the mean (SD) DCI score was 2.1 (2.2) for the AD cohort versus 1.2 (1.8) for the non-AD cohort (P <.0001). The prevalence of 12 of the 14 conditions that comprise the DCI was significantly higher in the AD cohort than in the non-AD cohort (P <.003). Table 2 also lists other chronic comorbidities occurring in the AD and non-AD cohorts. All of these comorbidities (anxiety, cardiac arrhythmias, cardiomyopathy, depression, dyslipidemia, epilepsy, hypertension, osteoporosis, other nonorganic psychoses, Parkinson’s disease) were more frequently identified among those persons in the AD cohort (P <.0001). The percentage of patients with at least 1 claim for Parkinson disease was 10-fold higher in the AD cohort than in the non-AD cohort. Epilepsy was 6 times more prevalent, depression was 5 times more prevalent, and anxiety was 3 times more prevalent in the AD cohort than in the non-AD cohort.
PDF is available on the last page.